Cargando…
A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials
The recent prospect of pharmaceutical interventions for cognitive impairment of Down syndrome (DS) has boosted a number of clinical trials in this population. However, running the trials has raised some methodological challenges and questioned the prevailing methodology used to evaluate cognitive fu...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4455308/ https://www.ncbi.nlm.nih.gov/pubmed/26089807 http://dx.doi.org/10.3389/fpsyg.2015.00708 |
_version_ | 1782374741409005568 |
---|---|
author | de Sola, Susana de la Torre, Rafael Sánchez-Benavides, Gonzalo Benejam, Bessy Cuenca-Royo, Aida del Hoyo, Laura Rodríguez, Joan Catuara-Solarz, Silvina Sanchez-Gutierrez, Judit Dueñas-Espin, Ivan Hernandez, Gimena Peña-Casanova, Jordi Langohr, Klaus Videla, Sebastia Blehaut, Henry Farre, Magi Dierssen, Mara |
author_facet | de Sola, Susana de la Torre, Rafael Sánchez-Benavides, Gonzalo Benejam, Bessy Cuenca-Royo, Aida del Hoyo, Laura Rodríguez, Joan Catuara-Solarz, Silvina Sanchez-Gutierrez, Judit Dueñas-Espin, Ivan Hernandez, Gimena Peña-Casanova, Jordi Langohr, Klaus Videla, Sebastia Blehaut, Henry Farre, Magi Dierssen, Mara |
author_sort | de Sola, Susana |
collection | PubMed |
description | The recent prospect of pharmaceutical interventions for cognitive impairment of Down syndrome (DS) has boosted a number of clinical trials in this population. However, running the trials has raised some methodological challenges and questioned the prevailing methodology used to evaluate cognitive functioning of DS individuals. This is usually achieved by comparing DS individuals to matched healthy controls of the same mental age. We propose a new tool, the TESDAD Battery that uses comparison with age-matched typically developed adults. This is an advantageous method for probing the clinical efficacy of DS therapies, allowing the interpretation and prediction of functional outcomes in clinical trials. In our DS population the TESDAD battery permitted a quantitative assessment of cognitive defects, which indicated language dysfunction and deficits in executive function, as the most important contributors to other cognitive and adaptive behavior outcomes as predictors of functional change in DS. Concretely, auditory comprehension and functional academics showed the highest potential as end-point measures of therapeutic intervention for clinical trials: the former as a cognitive key target for therapeutic intervention, and the latter as a primary functional outcome measure of clinical efficacy. Our results also emphasize the need to explore the modulating effects of IQ, gender and age on cognitive enhancing treatments. Noticeably, women performed significantly better than men of the same age and IQ in most cognitive tests, with the most consistent differences occurring in memory and executive functioning and negative trends rarely emerged on quality of life linked to the effect of age after adjusting for IQ and gender. In sum, the TESDAD battery is a useful neurocognitive tool for probing the clinical efficacy of experimental therapies in interventional studies in the DS population suggesting that age-matched controls are advantageous for determining normalization of DS. |
format | Online Article Text |
id | pubmed-4455308 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-44553082015-06-18 A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials de Sola, Susana de la Torre, Rafael Sánchez-Benavides, Gonzalo Benejam, Bessy Cuenca-Royo, Aida del Hoyo, Laura Rodríguez, Joan Catuara-Solarz, Silvina Sanchez-Gutierrez, Judit Dueñas-Espin, Ivan Hernandez, Gimena Peña-Casanova, Jordi Langohr, Klaus Videla, Sebastia Blehaut, Henry Farre, Magi Dierssen, Mara Front Psychol Psychology The recent prospect of pharmaceutical interventions for cognitive impairment of Down syndrome (DS) has boosted a number of clinical trials in this population. However, running the trials has raised some methodological challenges and questioned the prevailing methodology used to evaluate cognitive functioning of DS individuals. This is usually achieved by comparing DS individuals to matched healthy controls of the same mental age. We propose a new tool, the TESDAD Battery that uses comparison with age-matched typically developed adults. This is an advantageous method for probing the clinical efficacy of DS therapies, allowing the interpretation and prediction of functional outcomes in clinical trials. In our DS population the TESDAD battery permitted a quantitative assessment of cognitive defects, which indicated language dysfunction and deficits in executive function, as the most important contributors to other cognitive and adaptive behavior outcomes as predictors of functional change in DS. Concretely, auditory comprehension and functional academics showed the highest potential as end-point measures of therapeutic intervention for clinical trials: the former as a cognitive key target for therapeutic intervention, and the latter as a primary functional outcome measure of clinical efficacy. Our results also emphasize the need to explore the modulating effects of IQ, gender and age on cognitive enhancing treatments. Noticeably, women performed significantly better than men of the same age and IQ in most cognitive tests, with the most consistent differences occurring in memory and executive functioning and negative trends rarely emerged on quality of life linked to the effect of age after adjusting for IQ and gender. In sum, the TESDAD battery is a useful neurocognitive tool for probing the clinical efficacy of experimental therapies in interventional studies in the DS population suggesting that age-matched controls are advantageous for determining normalization of DS. Frontiers Media S.A. 2015-06-04 /pmc/articles/PMC4455308/ /pubmed/26089807 http://dx.doi.org/10.3389/fpsyg.2015.00708 Text en Copyright © 2015 de Sola, de la Torre, Sánchez-Benavides, Benejam, Cuenca-Royo, del Hoyo, Rodríguez, Catuara-Solarz, Sanchez-Gutierrez, Dueñas-Espin, Hernandez, Peña-Casanova, Langohr, Videla, Blehaut, Farre, Dierssen and The TESDAD Study Group. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Psychology de Sola, Susana de la Torre, Rafael Sánchez-Benavides, Gonzalo Benejam, Bessy Cuenca-Royo, Aida del Hoyo, Laura Rodríguez, Joan Catuara-Solarz, Silvina Sanchez-Gutierrez, Judit Dueñas-Espin, Ivan Hernandez, Gimena Peña-Casanova, Jordi Langohr, Klaus Videla, Sebastia Blehaut, Henry Farre, Magi Dierssen, Mara A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials |
title | A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials |
title_full | A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials |
title_fullStr | A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials |
title_full_unstemmed | A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials |
title_short | A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials |
title_sort | new cognitive evaluation battery for down syndrome and its relevance for clinical trials |
topic | Psychology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4455308/ https://www.ncbi.nlm.nih.gov/pubmed/26089807 http://dx.doi.org/10.3389/fpsyg.2015.00708 |
work_keys_str_mv | AT desolasusana anewcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials AT delatorrerafael anewcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials AT sanchezbenavidesgonzalo anewcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials AT benejambessy anewcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials AT cuencaroyoaida anewcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials AT delhoyolaura anewcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials AT rodriguezjoan anewcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials AT catuarasolarzsilvina anewcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials AT sanchezgutierrezjudit anewcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials AT duenasespinivan anewcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials AT hernandezgimena anewcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials AT penacasanovajordi anewcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials AT langohrklaus anewcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials AT videlasebastia anewcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials AT blehauthenry anewcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials AT farremagi anewcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials AT dierssenmara anewcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials AT anewcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials AT desolasusana newcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials AT delatorrerafael newcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials AT sanchezbenavidesgonzalo newcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials AT benejambessy newcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials AT cuencaroyoaida newcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials AT delhoyolaura newcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials AT rodriguezjoan newcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials AT catuarasolarzsilvina newcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials AT sanchezgutierrezjudit newcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials AT duenasespinivan newcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials AT hernandezgimena newcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials AT penacasanovajordi newcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials AT langohrklaus newcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials AT videlasebastia newcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials AT blehauthenry newcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials AT farremagi newcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials AT dierssenmara newcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials AT newcognitiveevaluationbatteryfordownsyndromeanditsrelevanceforclinicaltrials |